Browse News
Filter News
Found 70 articles
-
BioSpace Movers & Shakers, Oct. 29
10/29/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Onchilles Pharma Appoints Christopher Twitty, Ph.D., Chief Scientific Officer
10/26/2021
Onchilles Pharma announced today the expansion of the company’s scientific team with key leadership appointments.
-
Tentarix Biotherapeutics Emerges with $50 Million Series A
10/14/2021
Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital.
-
Asher Bio began two years ago and raised $55 million in a Series A financing round this March to take forward a series of engineered cytokines that aim to eliminate both the toxicities and the loss of efficacy in immunotherapy.
-
BioSpace Movers & Shakers, Aug. 27
8/27/2021
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Lengo Therapeutics Appoints Enoch K. Kariuki as Chief Executive Officer
6/28/2021
Lengo Therapeutics today announced the appointment of Enoch K. Kariuki, Pharm.D., as Chief Executive Officer.
-
Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors
6/10/2021
Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it raised $107 million in a Series B financing.
-
BioSpace Movers & Shakers, April 23
4/23/2021
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers. -
Lumen Bioscience Announces Appointment of Marcos Milla, Ph.D. to Board of Directors & Expansion of Leadership Team
4/22/2021
Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the appointment of Marcos Milla, Ph.D., to the company's board of directors and the expansion of its leadership team
-
Janux Therapeutics Appoints Charles Winter Senior Vice President of Chemistry, Manufacturing, and Controls
3/30/2021
Janux Therapeutics, a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Charles Winter as Senior Vice President of Chemistry, Manufacturing, and Controls (CMC)
-
Targeted immunotherapy company Asher Bio launched today with a $55 million Series A round led by Third Rock Ventures, aiming to move its lead engineered interleukin-2 (IL-2) therapy into human testing next year.
-
Janux Therapeutics Appoints Vickie Capps and Dr. Sheila Gujrathi to Board of Directors
3/18/2021
Janux Therapeutics today announced the appointment of Vickie Capps and Sheila Gujrathi, M.D., as independent members of the Company’s Board of Directors.
-
Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors
2/10/2021
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Enoch Kariuki, PharmD, to its Board of Directors
-
Over the course of 2020, Sanofi saw significant growth in its specialty care sales primarily driven by its blue-chip asset, Dupixent, as well as an increase in vaccine sales that were driven by demand for differentiated influenza vaccines, the company announced in its year-end financial report.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Imago BioSciences Appoints Enoch Kariuki to Board of Directors
2/2/2021
Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that its board has appointed a new independent director, Enoch Kariuki, PharmD., who most recently served as the chief financial officer of VelosBio.
-
The deal adds Kymab’s lead asset KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L.
-
Frank Nestle, Sanofi’s chief scientific officer and Global Head of Research, and Dietmar Berger, Sanofi’s chief medical officer and Global Head of Development, provided an overview of the company’s clinical activities and highlighted some assets that will be key revenue drives for the company.
-
BioSpace Movers & Shakers, November 13
11/13/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Silverback Therapeutics Expands Executive Team With Appointment of Healthcare Investment Banking Veteran Jonathan Piazza as Chief Financial Officer
11/10/2020
Silverback Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer and other serious diseases, today announced the appointment of Jonathan Piaz